A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies

Miranda E. Orr, A. Campbell Sullivan, Susan E Frost

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction. In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)637-648
Number of pages12
JournalTrends in Pharmacological Sciences
Volume38
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Tauopathies
tau Proteins
Brain
Therapeutics
Neurodegenerative Diseases
Protein Aggregates

Keywords

  • Alzheimer's disease
  • metabolic syndrome
  • neurodegeneration
  • tau
  • tauopathy
  • traumatic brain injury

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

A Brief Overview of Tauopathy : Causes, Consequences, and Therapeutic Strategies. / Orr, Miranda E.; Sullivan, A. Campbell; Frost, Susan E.

In: Trends in Pharmacological Sciences, Vol. 38, No. 7, 01.07.2017, p. 637-648.

Research output: Contribution to journalReview article

@article{695aa64691cc474690174d82bd3a88d8,
title = "A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies",
abstract = "There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction. In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.",
keywords = "Alzheimer's disease, metabolic syndrome, neurodegeneration, tau, tauopathy, traumatic brain injury",
author = "Orr, {Miranda E.} and Sullivan, {A. Campbell} and Frost, {Susan E}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.tips.2017.03.011",
language = "English (US)",
volume = "38",
pages = "637--648",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - A Brief Overview of Tauopathy

T2 - Causes, Consequences, and Therapeutic Strategies

AU - Orr, Miranda E.

AU - Sullivan, A. Campbell

AU - Frost, Susan E

PY - 2017/7/1

Y1 - 2017/7/1

N2 - There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction. In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.

AB - There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction. In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.

KW - Alzheimer's disease

KW - metabolic syndrome

KW - neurodegeneration

KW - tau

KW - tauopathy

KW - traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85018664098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018664098&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2017.03.011

DO - 10.1016/j.tips.2017.03.011

M3 - Review article

C2 - 28455089

AN - SCOPUS:85018664098

VL - 38

SP - 637

EP - 648

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 7

ER -